Early research (Phase 1)Not Yet RecruitingNCT05995015What this trial is testing4SCAR19U T Cells Targeting B Cell MalignanciesWho this might be right forB Cell Malignancies Shenzhen Geno-Immune Medical Institute 30
Very early researchUnknownNCT05105867What this trial is testingCD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell MalignanciesWho this might be right forRelapsed or Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed or Refractory B-cell Non-hodgkin Lymphoma 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 15
Early research (Phase 1)UnknownNCT03574168What this trial is testingCD19-CAR-T Cells in Patients With R/R B-ALLWho this might be right forB-cell Acute Lymphoblastic Leukemia Bioceltech Therapeutics, Ltd. 40
Early research (Phase 1)Not Yet RecruitingNCT07043218What this trial is testingA Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaWho this might be right forB-cell Acute Lymphoblastic Leukemia Shanghai Tongji Hospital, Tongji University School of Medicine 36
Testing effectiveness (Phase 2)Study completedNCT04325841What this trial is testingPhase II Study of Anti-CD19 CAR-T Cells Treating Leukemia ChildrenWho this might be right forAcute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia Beijing Boren Hospital 2
Very early researchUnknownNCT06277011What this trial is testingSafety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical ResearchWho this might be right forAcute Lymphoblastic LeukemiaNon-hodgkin Lymphoma Anhui Provincial Hospital 18
Testing effectiveness (Phase 2)UnknownNCT06503094What this trial is testingCD19 & CD20 Bispecific CAR T Cells for Relapsed / Refractory B Cell Hematological TumorsWho this might be right forB-Cell Lymphoblastic Leukemia/Lymphoma Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Early research (Phase 1)Ended earlyNCT00643240What this trial is testingYttrium Y 90 Anti-CD19 Antibody BU-12 in Patients With Advanced Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Lymphocytic LeukemiaWho this might be right forLeukemia Masonic Cancer Center, University of Minnesota 1
Testing effectiveness (Phase 2)UnknownNCT03902197What this trial is testingCD19 hsCAR-T for Refractory/Relapsed CD19+ B-ALL PatientsWho this might be right forAcute Lymphoblastic Leukemia Xuanwu Hospital, Beijing 50
Testing effectiveness (Phase 2)Looking for participantsNCT07244406What this trial is testingAssessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALLWho this might be right forB-ALL Hebei Senlang Biotechnology Inc., Ltd. 59
Early research (Phase 1)Temporarily pausedNCT06447987What this trial is testingHumanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic LeukemiaWho this might be right forRecurrent Acute Lymphoblastic LeukemiaRefractory Acute Lymphoblastic Leukemia City of Hope Medical Center 24
Early research (Phase 1)Looking for participantsNCT02508038What this trial is testingAlpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid TumorsWho this might be right forAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaHodgkin Lymphoma+8 more University of Wisconsin, Madison 22
Early research (Phase 1)UnknownNCT03018093What this trial is testingA Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALLWho this might be right forRelapsed or Refractory Acute Lymphoblastic Leukemia Shanghai AbelZeta Ltd. 20
Testing effectiveness (Phase 2)Ended earlyNCT01685021What this trial is testingStudy of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)Who this might be right forAcute Lymphoblastic Leukemia MorphoSys AG 22
Early research (Phase 1)Looking for participantsNCT05054257What this trial is testingCART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's LymphomaWho this might be right forRelapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma RefractoryNon-Hodgkin's Lymphoma, Relapsed Institute of Hematology and Blood Transfusion, Czech Republic 10
Testing effectiveness (Phase 2)Study completedNCT06705530What this trial is testingEvaluate the Tolerability, Safety, and Efficacy of an Anti-CD19 CAR-T Product in Patients With B-cell Lymphoproliferative DisordersWho this might be right forNon-Hodgkin Lymphoma, B-cellAcute Lymphoblastic Leukemia ALL National Research Center for Hematology, Russia 58
Testing effectiveness (Phase 2)UnknownNCT02892695What this trial is testingPCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and LymphomaWho this might be right forAcute Lymphocytic LeukemiaChronic Lymphocytic LeukemiaFollicular Lymphoma+3 more PersonGen BioTherapeutics (Suzhou) Co., Ltd. 10
Testing effectiveness (Phase 2)UnknownNCT03366350What this trial is testingAnti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell MalignanciesWho this might be right forAcute Lymphoblastic LeukemiaB Cell Lymphoma Wuhan Sian Medical Technology Co., Ltd 50
Early research (Phase 1)Looking for participantsNCT06080191What this trial is testingAllogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALLWho this might be right forB-cell Acute Lymphoblastic Leukemia Bambino Gesù Hospital and Research Institute 24
Testing effectiveness (Phase 2)Ended earlyNCT03743246What this trial is testingEvaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)Who this might be right forPrecursor Cell Lymphoblastic Leukemia-LymphomaLymphoma, Non-Hodgkin Celgene 21